Related Experiment Videos
Screening for cervical cancer in the developing world.
1Department of Obstetrics and Gynaecology, University of the Free State, P.O. Box 339, Bloemfontein 9300, South Africa. gnoghsc.md@mail.uovs.ac.za
Best Practice & Research. Clinical Obstetrics & Gynaecology
|September 10, 2005
Summary
Cervical cancer screening is challenging in low-income countries due to Pap smear limitations. Human papillomavirus vaccination offers a promising strategy for cervical cancer control.
Area of Science:
- Oncology
- Public Health
- Virology
Background:
- Cervical cancer is a leading cause of death among women in low-income nations.
- Existing screening methods like the Pap smear have significant limitations, including high cost, low sensitivity, and logistical challenges for mass implementation.
- Alternative screening approaches often lack clear advantages, being complex, costly, or having low specificity.
Purpose of the Study:
- To review the challenges associated with cervical cancer screening in resource-limited settings.
- To explore the potential of human papillomavirus (HPV) vaccination as a primary or therapeutic strategy for cervical cancer control.
Main Methods:
- Review of current cervical cancer screening modalities and their limitations.
- Analysis of the potential benefits and challenges of HPV vaccination in diverse healthcare settings.
Main Results:
- Pap smear screening is hampered by cost, sensitivity, expertise, and logistical demands, making population-wide coverage difficult.
- Combinational screening tests, while improving sensitivity, introduce complexity and reduce specificity.
- HPV vaccination emerges as a highly promising intervention for both prevention and treatment of cervical cancer.
Conclusions:
- Effective cervical cancer screening remains an unmet need in many developing countries.
- Human papillomavirus vaccination represents the most significant advancement for controlling cervical cancer, offering preventative and therapeutic potential.